Post Reply
561-580 of 1587
Such factual good news. Will be above $0.2 in no time.
noobnub ( Date: 31-Mar-2020 09:23) Posted:
|
low liquidity later drop down also very fast
noobnub ( Date: 31-Mar-2020 08:44) Posted:
|
https://www.straitstimes.com/world/europe/test-test-test-who-chief-tedros-coronavirus-message-to-world
The article on WHO shows the importance of testing against the fight with COVID19.
The article on WHO shows the importance of testing against the fight with COVID19.
any shorting opp?
Hahaha won?t gap up 0.2 lah but will make money leh.
We conservative says one tear kit charge 5 cents enough. 1m in indonesia order only already 500k. But Indonesia alone has 200 over mil population. And friends sources says they in need of kits. Then still for so many countries wanna buy. Each counties avg buy 1mil pcs. 30 countries order how much liao 15mil just from this crisis
I?m not vested ah I just think think
We conservative says one tear kit charge 5 cents enough. 1m in indonesia order only already 500k. But Indonesia alone has 200 over mil population. And friends sources says they in need of kits. Then still for so many countries wanna buy. Each counties avg buy 1mil pcs. 30 countries order how much liao 15mil just from this crisis
I?m not vested ah I just think think
uiop1223 ( Date: 30-Mar-2020 20:31) Posted:
|
Just test kit to be used in singapore... how much can a test kit earn? Dont get too excited bah
Seems like possible to Gap up to $0.2?
Joelton ( Date: 30-Mar-2020 17:59) Posted:
|
https://www.biolidics.com/newsroom/biolidics-covid19-OEM-press-release-final.pdf
Biolidics To Launch Its Rapid Test Kit For COVID-19 Obtains Approval From Singapore&rsquo s Health Sciences Authority For Its Rapid Test Kit To Be Used In Singapore
&bull The COVID-19 outbreak has been declared a pandemic and there are more than 720,000 confirmed cases(1) with rising number of new cases globally on a daily basis
&bull Biolidics&rsquo easy-to-use rapid test kit can detect COVID-19 using serum, plasma or whole blood samples with an accuracy of more than 95% in 10 minutes
&bull Singapore&rsquo s Health Sciences Authority has given provisional authorisation for the rapid test kit to be used in Singapore
&bull The World Health Organisation has recently called on all countries to ramp up their testing programmes as it is the best way to slow the advance of the COVID-19 pandemic
Singapore, 30 March 2020 &ndash Biolidics Limited (&ldquo Biolidics&rdquo or the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ), a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce it has launched its rapid test kit for the Novel Coronavirus 2019 (&ldquo COVID-19&rdquo ) and it has entered into a manufacturer agreement with a diagnostic kit manufacturer to customise and manufacture the rapid test kits. The first batch of Biolidics&rsquo rapid test kits is expected to be available in April 2020.
Working in close collaboration with the diagnostic kit manufacturer, the rapid test kit has undergone extensive validation in compliance to ISO13485 requirements.
Using serum, plasma or whole blood samples, Biolidics&rsquo rapid test kit can detect COVID-19 with an accuracy of more than 95% in 10 minutes.
Notably, Biolidics has obtained provisional authorisation from Singapore&rsquo s Health Science Authority for its rapid test kit to be used in Singapore.
In addition, Biolidics is working closely with Clearbridge Health Limited (&ldquo Clearbridge Health&rdquo ) to obtain the relevant approval and/or authorisation from the various health authorities in the region for the use of the rapid test kit.
Leveraging on Clearbridge Health&rsquo s distribution platform of healthcare solutions and technologies in Asia, particularly in Philippines, Malaysia, Indonesia and Hong Kong, Biolidics is also looking to market and deploy its rapid test kit in these countries once the relevant approval and/or authorization is obtained in the respective countries.
Biolidics&rsquo rapid test kit is easy-to-use and can enable more effective and efficient decentralized screening among suspected patients. As such, the rapid test kit is suitable to be used for screening of suspected patients in the following scenarios, among others:
- Points of border entry
- Potential COVID-19 clusters
Currently, polymerase chain reaction (&ldquo PCR&rdquo ) testing is used to confirm patients with COVID19 but it is a laboratory technique and requires laboratory specialists and dedicated medical testing equipment, hence PCR testing for COVID-19 generally requires at least 3 hours to obtain the test results.
The Covid-19 has been declared a pandemic by World Health Organisation (&ldquo WHO&rdquo ) and there are more than 720,000 confirmed cases with rising number of new cases globally on a daily basis.
On 16 March 2020, WHO has called on all countries to ramp up their testing programmes as it is the best way to slow the advance of the coronavirus pandemic(2) .
Given the increasing concerns over the spread of COVID-19, there is a growing demand for a simple, fast and accurate solution to control and reduce the spread of COVID-19.
Mr Jeremy Yee ( 余 斌 ), Non-Executive Non-Independent Chairman of Biolidics, said, &ldquo Developing affordable, accurate test kits for COVID-19 have been one of the biggest challenges in the pandemic. Hence, I would like to express special thanks to the collective efforts and commitment of our team to accelerate the development and commercialisation of our rapid test kit for COVID-19.&rdquo
Dr Leong Man Chun, Interim Chief Executive Officer of Biolidics, added, &ldquo Testing for COVID19 is vital to track and contain the pandemic which has spread rapidly across the world. Utilising Biolidics&rsquo rapid test kit, we can enable point-of-care testing for larger pool of clusters, resulting in more effective and efficient decentralized screening among suspected cases. With faster and accurate results, it can guide treatment decisions and further enhance public safety measures.&rdquo
Dr Wang Qing-Yin, Chief Operating Officer of Biolidics, concluded, &ldquo As Biolidics continues to evolve into a diagnostic-focused medical technology company, we aim to develop a broader portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes.&rdquo
Biolidics To Launch Its Rapid Test Kit For COVID-19 Obtains Approval From Singapore&rsquo s Health Sciences Authority For Its Rapid Test Kit To Be Used In Singapore
&bull The COVID-19 outbreak has been declared a pandemic and there are more than 720,000 confirmed cases(1) with rising number of new cases globally on a daily basis
&bull Biolidics&rsquo easy-to-use rapid test kit can detect COVID-19 using serum, plasma or whole blood samples with an accuracy of more than 95% in 10 minutes
&bull Singapore&rsquo s Health Sciences Authority has given provisional authorisation for the rapid test kit to be used in Singapore
&bull The World Health Organisation has recently called on all countries to ramp up their testing programmes as it is the best way to slow the advance of the COVID-19 pandemic
Singapore, 30 March 2020 &ndash Biolidics Limited (&ldquo Biolidics&rdquo or the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ), a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce it has launched its rapid test kit for the Novel Coronavirus 2019 (&ldquo COVID-19&rdquo ) and it has entered into a manufacturer agreement with a diagnostic kit manufacturer to customise and manufacture the rapid test kits. The first batch of Biolidics&rsquo rapid test kits is expected to be available in April 2020.
Working in close collaboration with the diagnostic kit manufacturer, the rapid test kit has undergone extensive validation in compliance to ISO13485 requirements.
Using serum, plasma or whole blood samples, Biolidics&rsquo rapid test kit can detect COVID-19 with an accuracy of more than 95% in 10 minutes.
Notably, Biolidics has obtained provisional authorisation from Singapore&rsquo s Health Science Authority for its rapid test kit to be used in Singapore.
In addition, Biolidics is working closely with Clearbridge Health Limited (&ldquo Clearbridge Health&rdquo ) to obtain the relevant approval and/or authorisation from the various health authorities in the region for the use of the rapid test kit.
Leveraging on Clearbridge Health&rsquo s distribution platform of healthcare solutions and technologies in Asia, particularly in Philippines, Malaysia, Indonesia and Hong Kong, Biolidics is also looking to market and deploy its rapid test kit in these countries once the relevant approval and/or authorization is obtained in the respective countries.
Biolidics&rsquo rapid test kit is easy-to-use and can enable more effective and efficient decentralized screening among suspected patients. As such, the rapid test kit is suitable to be used for screening of suspected patients in the following scenarios, among others:
- Points of border entry
- Potential COVID-19 clusters
Currently, polymerase chain reaction (&ldquo PCR&rdquo ) testing is used to confirm patients with COVID19 but it is a laboratory technique and requires laboratory specialists and dedicated medical testing equipment, hence PCR testing for COVID-19 generally requires at least 3 hours to obtain the test results.
The Covid-19 has been declared a pandemic by World Health Organisation (&ldquo WHO&rdquo ) and there are more than 720,000 confirmed cases with rising number of new cases globally on a daily basis.
On 16 March 2020, WHO has called on all countries to ramp up their testing programmes as it is the best way to slow the advance of the coronavirus pandemic(2) .
Given the increasing concerns over the spread of COVID-19, there is a growing demand for a simple, fast and accurate solution to control and reduce the spread of COVID-19.
Mr Jeremy Yee ( 余 斌 ), Non-Executive Non-Independent Chairman of Biolidics, said, &ldquo Developing affordable, accurate test kits for COVID-19 have been one of the biggest challenges in the pandemic. Hence, I would like to express special thanks to the collective efforts and commitment of our team to accelerate the development and commercialisation of our rapid test kit for COVID-19.&rdquo
Dr Leong Man Chun, Interim Chief Executive Officer of Biolidics, added, &ldquo Testing for COVID19 is vital to track and contain the pandemic which has spread rapidly across the world. Utilising Biolidics&rsquo rapid test kit, we can enable point-of-care testing for larger pool of clusters, resulting in more effective and efficient decentralized screening among suspected cases. With faster and accurate results, it can guide treatment decisions and further enhance public safety measures.&rdquo
Dr Wang Qing-Yin, Chief Operating Officer of Biolidics, concluded, &ldquo As Biolidics continues to evolve into a diagnostic-focused medical technology company, we aim to develop a broader portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes.&rdquo
Every stocks go up except this today .
Low volume trading but look like someone collecting because 2 married deals total 2mil lots at high prices
0.103... is this share collapsing?
Asian healthcare investment booms, offers &lsquo double bottom line&rsquo for private equity
Healthcare-focused private equity firm Quadria Capital has what may be called a leisurely approach to investing in what is an increasingly active sector.
Healthcare-focused private equity firm Quadria Capital has what may be called a leisurely approach to investing in what is an increasingly active sector.
These married deals are done at much higher than market price ????
Again today married deal one million
Insiders know something we don know ??
Insiders know something we don know ??
1 million shares done @.133 married deal
Biolidics to raise S$3.1m from share placement for expansion
CANCER diagnostics company Biolidics on Monday said it will undertake a share placement to raise about S$3.1 million to fuel its business expansion and pursue new growth opportunities.
The Catalist-listed company will issue about 17.9 million new ordinary shares at 17.5 Singapore cents each.This issue price represents about a 7.3 per cent discount to the counter' s volume weighted average price of 18.88 Singapore cents per share for all trades done on Friday.
Most of the 21 subscribers in the placement are private investors. The majority are also existing shareholders with stakes in Biolidocs ranging from 0.02 per cent to 2.3 per cent, and the remaining nine will become new shareholders.
After the placement, the subscribers will hold stakes ranging from 0.04 per cent to 2.91 per cent in Biolidics.
The only company among the placees is Kenyon, a Singapore-incorporated firm with businesses in building construction, engineering design and consulting activities. Kenyon will pay S$350,000 to increase its stake in Biolidics to 2.91 per cent from its current 2.3 per cent shareholding.
The placement shares in total represent some 7.36 per cent of Biolidics' existing share capital, and will represent about 6.86 per cent of its enlarged share capital.
Biolidics said that each of the subscribers had previously expressed an interest to invest or further invest in the company. Biolidics independently approached these subscribers.
The company also said it understands that the subscribers are participating in the placement " purely for financial investment purposes" .
Of the S$3.1 million in estimated net proceeds, Biolidics intends to use around half of it - about S$1.6 million - to expand the group' s presence in its existing markets and into new market segments, and to establish new sales channels.
About S$792,000 or roughly one-quarter of the net proceeds will go into expanding the company' s businesses through investments, mergers and acquisitions, joint ventures and/or strategy collaborations with third parties.
The remaining S$711,000 or about 23 per cent of the net proceeds will be used for general working capital purposes.
Shares of Biolidics closed flat at 20.5 Singapore cents on Friday.
https://www.businesstimes.com.sg/companies-markets/biolidics-to-raise-s31m-from-share-placement-for-expansion
PHILLIP SECURITIES INITATED buy 26cents...it time to rock n roll fellow punters out there..
Stanislaus Jude Chan 10/03/2020, 1:02pm
SINGAPORE (Mar 10): Phillip Securities Research is reiterating its confidence in healthcare player Clearbridge Health, on the back of the expansion of its regional footprint.
The optimism comes despite Clearbridge posting a set of results for FY2019 ended December that came in below expectations.
Clearbridge narrowed its losses to $10.6 million for FY2019, a 42.8% improvement from losses of $18.4 million a year ago.
While the group remains loss-making, Phillip notes that Clearbridge turned EBITDA positive in 2HFY2019.
Excluding one-offs, share option expenses and R& D expenses, Clearbridge recorded EBITDA of $0.38 million in 3QFY2019. EBITDA then grew 44.8% quarter-on-quarter to hit $0.55 million in 4QFY2019.
And Phillip forecasts that the company will clock another year of positive EBITDA in FY2020.
The brokerage is keeping its &ldquo buy&rdquo call on Clearbridge Health with an unchanged target price of 26 cents.
FY2019 revenue more than trebled to $21.5 million, from $6.1 million a year ago.
The top-line growth was driven by strong contributions from its healthcare acquisitions during the year.
&ldquo The early years of Clearbridge Health will be spent building its regional footprint,&rdquo says Phillip&rsquo s research team in a March 10 report. &ldquo We believe Clearbridge Health is focused on organic growth of its acquisitions through investing into newer facilities, larger economies of scale in operations, cross-sell and introduce more complex services across their regional platform.&rdquo
Already, Clearbridge has expanded its regional presence to include Singapore, Indonesia, Philippines, Malaysia and Hong Kong.
In particular, PT Indo Genesis Medika (IGM), which was acquired in May 2019, contributed some $10.3 million, or 48% of total group revenue for FY2019.
Meanwhile, Clearbridge Medical Philippines, a 4-storey facility in Manila, is also seeing improving patient flow following the completion of its renovation in 1HFY2019.
In Singapore, the group is also expected to benefit from the acquisition of nine clinics under the Dental Focus Group in September 2019.
&ldquo In emerging markets, general practitioner (GP) clinics will be less profitable due to the practice of self-medication. However, dentistry cannot be self-medicated,&rdquo Phillip&rsquo s analysts say.
&ldquo We expect another year of strong growth for CBH. The largest contribution will come from recent acquisitions &ndash IGM and Dental Focus. Newly opened facilities in Malaysia and the Philippines will be another source,&rdquo the research team adds.
As at 12.50pm, shares in Clearbridge Health are trading 0.4 cent higher, or up 3.4%, at 12 cents.
This comes after the counter plunged 14.7% to close at an all-time low of 11.6 cents on March 9 &ndash the &ldquo Black Monday&rdquo which saw global markets plummet by record levels on the back of a Saudi-led oil price war as well as coronavirus fears.
Shares in Clearbridge are currently trading 57.1% lower than its initial public offering (IPO) price of 28 cents in December 2017, and 79.6% below its all-time peak of 58.8 cents in January 2018.
Stanislaus Jude Chan 10/03/2020, 1:02pm
SINGAPORE (Mar 10): Phillip Securities Research is reiterating its confidence in healthcare player Clearbridge Health, on the back of the expansion of its regional footprint.
The optimism comes despite Clearbridge posting a set of results for FY2019 ended December that came in below expectations.
Clearbridge narrowed its losses to $10.6 million for FY2019, a 42.8% improvement from losses of $18.4 million a year ago.
While the group remains loss-making, Phillip notes that Clearbridge turned EBITDA positive in 2HFY2019.
Excluding one-offs, share option expenses and R& D expenses, Clearbridge recorded EBITDA of $0.38 million in 3QFY2019. EBITDA then grew 44.8% quarter-on-quarter to hit $0.55 million in 4QFY2019.
And Phillip forecasts that the company will clock another year of positive EBITDA in FY2020.
The brokerage is keeping its &ldquo buy&rdquo call on Clearbridge Health with an unchanged target price of 26 cents.
FY2019 revenue more than trebled to $21.5 million, from $6.1 million a year ago.
The top-line growth was driven by strong contributions from its healthcare acquisitions during the year.
&ldquo The early years of Clearbridge Health will be spent building its regional footprint,&rdquo says Phillip&rsquo s research team in a March 10 report. &ldquo We believe Clearbridge Health is focused on organic growth of its acquisitions through investing into newer facilities, larger economies of scale in operations, cross-sell and introduce more complex services across their regional platform.&rdquo
Already, Clearbridge has expanded its regional presence to include Singapore, Indonesia, Philippines, Malaysia and Hong Kong.
In particular, PT Indo Genesis Medika (IGM), which was acquired in May 2019, contributed some $10.3 million, or 48% of total group revenue for FY2019.
Meanwhile, Clearbridge Medical Philippines, a 4-storey facility in Manila, is also seeing improving patient flow following the completion of its renovation in 1HFY2019.
In Singapore, the group is also expected to benefit from the acquisition of nine clinics under the Dental Focus Group in September 2019.
&ldquo In emerging markets, general practitioner (GP) clinics will be less profitable due to the practice of self-medication. However, dentistry cannot be self-medicated,&rdquo Phillip&rsquo s analysts say.
&ldquo We expect another year of strong growth for CBH. The largest contribution will come from recent acquisitions &ndash IGM and Dental Focus. Newly opened facilities in Malaysia and the Philippines will be another source,&rdquo the research team adds.
As at 12.50pm, shares in Clearbridge Health are trading 0.4 cent higher, or up 3.4%, at 12 cents.
This comes after the counter plunged 14.7% to close at an all-time low of 11.6 cents on March 9 &ndash the &ldquo Black Monday&rdquo which saw global markets plummet by record levels on the back of a Saudi-led oil price war as well as coronavirus fears.
Shares in Clearbridge are currently trading 57.1% lower than its initial public offering (IPO) price of 28 cents in December 2017, and 79.6% below its all-time peak of 58.8 cents in January 2018.
Nick90 ( Date: 12-Mar-2020 10:22) Posted:
|
Only this medic stock drop today....
https://www.straitstimes.com/singapore/who-declares-covid-19-outbreak-a-pandemic
WHO declares Covid-19 outbreak a pandemic
The World Health Organisation (WHO) yesterday declared the coronavirus outbreak a pandemic, citing the alarming levels of spread around the world.
" We are deeply concerned both by the alarming levels of spread and severity, and by the alarming levels of inaction. We have, therefore, made the assessment that Covid-19 can be characterised as a pandemic," said WHO director-general Tedros Adhanom Ghebreyesus at a news conference, adding that the organisation was not using the word lightly.
There are now over 120,000 cases in 114 countries.
In Singapore yesterday, 12 new Covid-19 cases were confirmed, including eight people who are believed to have caught the disease outside the Republic.
Of the four locally transmitted cases, one is linked to the private dinner at Safra Jurong another, a staff nurse at Ng Teng Fong General Hospital, is linked to an imported case from the Philippines while contact tracing is ongoing for the other two.
The latest update brings the number of cases here to 178. Three more patients were discharged.
Investing ideas
This healthcare stock could be a multibagger as share price plunges to all-time low
Stanislaus Jude Chan 10/03/2020, 1:02pm
SINGAPORE (Mar 10): Phillip Securities Research is reiterating its confidence in healthcare player Clearbridge Health, on the back of the expansion of its regional footprint.
The optimism comes despite Clearbridge posting a set of results for FY2019 ended December that came in below expectations.
Clearbridge narrowed its losses to $10.6 million for FY2019, a 42.8% improvement from losses of $18.4 million a year ago.
While the group remains loss-making, Phillip notes that Clearbridge turned EBITDA positive in 2HFY2019.
Excluding one-offs, share option expenses and R& D expenses, Clearbridge recorded EBITDA of $0.38 million in 3QFY2019. EBITDA then grew 44.8% quarter-on-quarter to hit $0.55 million in 4QFY2019.
And Phillip forecasts that the company will clock another year of positive EBITDA in FY2020.
The brokerage is keeping its &ldquo buy&rdquo call on Clearbridge Health with an unchanged target price of 26 cents.
FY2019 revenue more than trebled to $21.5 million, from $6.1 million a year ago.
The top-line growth was driven by strong contributions from its healthcare acquisitions during the year.
&ldquo The early years of Clearbridge Health will be spent building its regional footprint,&rdquo says Phillip&rsquo s research team in a March 10 report. &ldquo We believe Clearbridge Health is focused on organic growth of its acquisitions through investing into newer facilities, larger economies of scale in operations, cross-sell and introduce more complex services across their regional platform.&rdquo
Already, Clearbridge has expanded its regional presence to include Singapore, Indonesia, Philippines, Malaysia and Hong Kong.
In particular, PT Indo Genesis Medika (IGM), which was acquired in May 2019, contributed some $10.3 million, or 48% of total group revenue for FY2019.
Meanwhile, Clearbridge Medical Philippines, a 4-storey facility in Manila, is also seeing improving patient flow following the completion of its renovation in 1HFY2019.
In Singapore, the group is also expected to benefit from the acquisition of nine clinics under the Dental Focus Group in September 2019.
&ldquo In emerging markets, general practitioner (GP) clinics will be less profitable due to the practice of self-medication. However, dentistry cannot be self-medicated,&rdquo Phillip&rsquo s analysts say.
&ldquo We expect another year of strong growth for CBH. The largest contribution will come from recent acquisitions &ndash IGM and Dental Focus. Newly opened facilities in Malaysia and the Philippines will be another source,&rdquo the research team adds.
As at 12.50pm, shares in Clearbridge Health are trading 0.4 cent higher, or up 3.4%, at 12 cents.
This comes after the counter plunged 14.7% to close at an all-time low of 11.6 cents on March 9 &ndash the &ldquo Black Monday&rdquo which saw global markets plummet by record levels on the back of a Saudi-led oil price war as well as coronavirus fears.
Shares in Clearbridge are currently trading 57.1% lower than its initial public offering (IPO) price of 28 cents in December 2017, and 79.6% below its all-time peak of 58.8 cents in January 2018.